{"disease":{"id":"behcet-s-disease","name":"Behcet's disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":10,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"abrilada","indication_name":"Behcet's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrilada","generic_name":"Adalimumab-Afzb","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor necrosis factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":"10191","mechanism":"Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"chembl-chembl1201581","indication_name":"Behcet's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Remicade","generic_name":"INFLIXIMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"Tumor Necrosis Factor Blocker [EPC]","quality_score":73,"revenue":"4200","mechanism":"Remicade works by binding to and neutralizing tumor necrosis factor, a protein that promotes inflammation and tissue damage."},{"drug_id":"infliximab","indication_name":"Behcet's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Remicade","generic_name":"infliximab","company_name":"Johnson & Johnson","drug_phase":"discontinued","molecular_target":"TNFα","drug_class":"Monoclonal antibody","quality_score":43,"revenue":null,"mechanism":"Infliximab binds to TNFα, blocking its interaction with receptors, reducing inflammation and immune responses."},{"drug_id":"remicade","indication_name":"Behcet's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Remicade","company_name":"Shanghai Biomabs Pharmaceutical Co., Ltd.","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"inflectra","indication_name":"Behcet's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Remicade","generic_name":"Infliximab-Dyyb","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Tumor Necrosis Factor alpha (TNFα)","drug_class":"TNF blocker","quality_score":10,"revenue":null,"mechanism":"Infliximab-dyyb neutralizes TNFα by binding with high affinity to soluble and transmembrane forms, inhibiting receptor binding."},{"drug_id":"adalimumab-adbm","indication_name":"Behcet's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CYLTEZO","generic_name":"ADALIMUMAB-ADBM","company_name":"BOEHRINGER INGELHEIM","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"infliximab-qbtx","indication_name":"Behcet's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"IXIFI","generic_name":"INFLIXIMAB-QBTX","company_name":"PFIZER INC","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"azathioprine","indication_name":"Behcet's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imuran","generic_name":"AZATHIOPRINE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Purine Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"humira","indication_name":"Behcet's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Humira","company_name":"Sohag University","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adalimumab","indication_name":"Behcet's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humira","generic_name":"ADALIMUMAB","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor Necrosis Factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":null,"mechanism":"Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."}],"pipeline":[],"offLabel":[],"totalMarketed":10,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06766552","title":"A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04402086","title":"Rheumatology Patient Registry and Biorepository","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT07077304","title":"EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05200715","title":"AutoInflammatory Disease Alliance Registry (AIDA)","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"University of Siena","has_results":false},{"nct_id":"NCT05904301","title":"Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Santé Arménie French-Armenian Research Center","has_results":false},{"nct_id":"NCT01960790","title":"Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)","phase":"","overall_status":"COMPLETED","enrollment_count":473,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03410290","title":"Journey of Patients With Vasculitis From First Symptom to Diagnosis","phase":"","overall_status":"COMPLETED","enrollment_count":456,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT03531385","title":"Assessment of Central Sensitization, Neuropathic Pain, Sleep Quality and Daily Life Activities in Behcet's Disease","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Bursa Yuksek Ihtisas Training and Research Hospital","has_results":false},{"nct_id":"NCT06902428","title":"Evaluating the Efficacy and Safety of of HSK44459 in Patients With Behçet's Disease","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Haisco Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT06925698","title":"Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Marmara University","has_results":false},{"nct_id":"NCT01988506","title":"Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03543709","title":"Evaluation of Fibromyalgia With Disease Activity and Clinical Findings in Women With Behçet's Disease","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Bursa Yuksek Ihtisas Training and Research Hospital","has_results":false},{"nct_id":"NCT05999461","title":"Association of Auditory Dysfunction With Retinal Ischemia in Behcet Disease","phase":"","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT04065672","title":"Low-dose IL-2 Treatment on Behcet's Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"HeJing","has_results":false},{"nct_id":"NCT02687828","title":"A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients","phase":"","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03371095","title":"Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT01109433","title":"Immunogenetic Mechanisms in Behcet's Disease","phase":"","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT03522662","title":"Anti IL-18 (GSK1070806) in Behcet's Disease","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"Cambridge University Hospitals NHS Foundation Trust","has_results":false},{"nct_id":"NCT06276829","title":"Behçet and LDH/Albumin","phase":"","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"Ataturk University","has_results":false},{"nct_id":"NCT01211977","title":"A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}